Business News • PR NewsWire • New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and 4th Line Salvage Setting With and Without Prior Rituximab Treatment

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and 4th Line Salvage Setting With and Without Prior Rituximab Treatment

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and 4th Line Salvage Setting With and Without Prior Rituximab Treatment

SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from sub-set analyses of data from the Phase 3 EXTEND, or PIX301, clinical trial of PIXUVRI® (pixantrone). The analyses evaluated the efficacy of PIXUVRI in the...

View More : http://www.prnewswire.com/news-releases/new-extend-analyses-evaluate-efficacy-of-single-agent-pixuvri-in-3rd-and-4th-lin...

Releted News by prnewswire

Sony Pictures Television Garners Five Daytime Emmy Awards Including Outstanding Talk Show/ Informational for The Dr. Oz Show and Outstanding Drama Series for Days of our Lives

CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis